Facilitating Involvement in Twelve-Step Programs

Donovan, Dennis M.; Floyd, Anthony S.

doi:10.1007/978-0-387-77725-2_17

Cited by 23 publications

(21 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They found that AA attendance increased in both groups during active treatment and decreased again following the active phase of the study. These findings suggests that patients responded to their improvement by voluntarily attending more AA meetings and suggests further that a group-based intervention, whether it be CBT or, possibly, 12-Step facilitation (Donovan and Floyd, 2008) can be helpful to alcohol dependent patients with social anxiety.…”

Section: Resultsmentioning

confidence: 86%

Treatment of substance abusing patients with comorbid psychiatric disorders

Kelly

Daley

Douaihy

2012

Addictive Behaviors

223

163

View full text Add to dashboard Cite

Objective To update clinicians on the latest in evidence-based treatments for substance use disorders (SUD) and non-substance use disorders among adults and suggest how these treatments can be combined into an evidence based process that enhances treatment effectiveness in comorbid patients. Method Articles were extracted from Pubmed using the search terms “dual diagnosis,” “comorbidity” and “co-occurring” and were reviewed for evidence of effectiveness for pharmacologic and psychotherapeutic treatments of comorbidity. Results Twenty-four research reviews and 43 research trials were reviewed. The preponderance of the evidence suggests that antidepressants prescribed to improve substance-related symptoms among patients with mood and anxiety disorders are either not highly effective or involve risk due to high side-effect profiles or toxicity. Second-generation antipsychotics are more effective for treatment of schizophrenia and comorbid substance abuse and current evidence suggests clozapine, olanzapine and risperidone are among the best. Clozapine appears to be the most effective of the antipsychotics for reducing alcohol, cocaine and cannabis abuse among patients with schizophrenia. Motivational interviewing has robust support as a highly effective psychotherapy for establishing a therapeutic alliance. This finding is critical since retention in treatment is essential for maintaining effectiveness. Highly structured therapy programs that integrate intensive outpatient treatments, case management services and behavioral therapies such as Contingency Management (CM) are most effective for treatment of severe comorbid conditions. Conclusions Creative combinations of psychotherapies, behavioral and pharmacological interventions offer the most effective treatment for comorbidity. Intensity of treatment must be increased for severe comorbid conditions such as the schizophrenia/cannabis dependence comorbidity due to the limitations of pharmacological treatments.

show abstract

Section: Resultsmentioning

confidence: 86%

Treatment of substance abusing patients with comorbid psychiatric disorders

Kelly

Daley

Douaihy

2012

Addictive Behaviors

223

163

View full text Add to dashboard Cite

show abstract

“…There is strong research support for the ability of these therapies to increase attendance and active involvement in 12-Step fellowships, improve drinking or other substance use outcomes, and have long-lasting effects (Carroll, Nich, Ball, McCance, & Rounsaville, 1998; Carroll et al, 2000; Donovan & Floyd, 2008; Project Match Research Group, 1997; Timko DeBenedetti, & Billow; 2006; Timko & DeBenedetti, 2007). This is also true for studies focusing specifically on stimulant users (cocaine or methamphetamine).…”

Section: Introductionmentioning

confidence: 99%

Is level of exposure to a 12-step facilitation therapy associated with treatment outcome?

Wells

Donovan

Daley

et al. 2014

Journal of Substance Abuse Treatment

Self Cite

View full text Add to dashboard Cite

This study examined whether level of exposure to Stimulant Abuser Groups to Engage in 12-Step (STAGE-12), a 12-Step facilitative therapy, is related to treatment outcome. Data were from a large National Drug Abuse Treatment Clinical Trials Network (CTN) study comparing STAGE-12 combined with Treatment-as-Usual (TAU) to TAU alone. These analyses include only those randomized to STAGE-12 (n = 234). Assessments occurred at baseline and 30, 60, 90, and 180 days following randomization. High-exposure patients (n = 158; attended at least 2 of 3 individual, and 3 of 5 group, sessions), compared to those with less exposure (n = 76), demonstrated: (1) higher odds of self-reported abstinence from, and lower rates of, stimulant and non-stimulant drug use; (2) lower probabilities of stimulant-positive urines; (3) more days of attending and lower odds of not attending 12-Step meetings; (4) greater likelihood of reporting no drug problems; (5) more days of duties at meetings; and (6) more types of 12-Step activities. Many of these differences declined over time, but several were still significant by the last follow-up. Treatment and research implications are discussed.

show abstract

“…To note, it is known by sponsors and others at AA meetings as the “traditional wisdom” is to recommend against making major life decisions or changes (including quitting smoking) during the first year of recovery from alcohol. This stems out of fear those changes (including smoking cessation) would provoke a relapse to alcohol or drugs [35-38]. This culture may have a direct impact on patients’ thinking about reducing smoking or their ability to quit smoking.…”

Section: Discussionmentioning

confidence: 99%

Bupropion-SR for Smoking Reduction and Cessation in Alcohol-Dependent Outpatients: A Naturalistic, Open-Label Study

Karam‐Hage¹,

Robinson²,

Lodhi³

et al. 2014

CCP

View full text Add to dashboard Cite

Background We sought to determine whether sustained-release bupropion (bupropion-SR) reduces smoking and promotes smoking cessation among alcohol-dependent (AD) smokers while they are in early recovery from alcohol. Methods We conducted an open-label, naturalistic study among AD smokers enrolled in an outpatient treatment program. The treatment group (n=58) was offered bupropion-SR and brief smoking cessation counseling. A control group (n=57) was matched to the treatment group by age, sex, ethnicity, cigarette use, and years of alcohol dependence. The controls received no smoking cessation intervention. We collected tobacco and alcohol abstinence data for 6 months after enrollment. Results Participants in the treatment group were more likely to abstain from smoking than controls, at any of the follow-up time point. The treatment group smoked less cigarettes per day (CPD) at baseline, 30 days and 180 days post-baseline, compared to controls. These findings persisted after adjusting for possible covariates. Conclusion Bupropion-SR may be helpful to quit or reduce smoking for recently abstinent AD individuals.

show abstract

Facilitating Involvement in Twelve-Step Programs

Cited by 23 publications

References 75 publications

Treatment of substance abusing patients with comorbid psychiatric disorders

Treatment of substance abusing patients with comorbid psychiatric disorders

Is level of exposure to a 12-step facilitation therapy associated with treatment outcome?

Bupropion-SR for Smoking Reduction and Cessation in Alcohol-Dependent Outpatients: A Naturalistic, Open-Label Study

Contact Info

Product

Resources

About